Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.35
Bid: 4.20
Ask: 4.50
Change: 0.10 (2.35%)
Spread: 0.30 (7.143%)
Open: 4.25
High: 4.35
Low: 4.25
Prev. Close: 4.35
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Regulatory Approval- Organic Production Regulation

7 Jan 2020 07:00

RNS Number : 9140Y
Eden Research plc
07 January 2020
 

 

 

7 January 2020

 

Eden Research plc

 

("Eden" or "Company")

 

Eden's three EU-registered active ingredients approved in Organic Production Regulation

Eden Research plc (AIM: EDEN), the AIM quoted company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce that its three EU-registered active ingredients, geraniol, eugenol and thymol, have all been approved for use in organic farming following inclusion in the EU's Organic Production Regulation.

Organic farming covered 12.6 million hectares of agricultural land in the EU Member States in 2017, equivalent to 7% of the total utilised agricultural area. Between 2012-2017, land assigned for organic growing within these Member States increased by 25%. In Italy and Spain, the conversion rates from conventional to organic agriculture grew by over 60% with the share of organic production totalling 15.2% and 13.9% respectively.

Pursuant to this approval, Eden's products will provide organic growers with the high levels of efficacy often associated with conventional chemical pesticides, thereby providing the Company's growers with another alternative and sustainable solution.

Sean Smith, CEO of Eden Research commented: "We are very excited by this approval for EU organic farming as this opens up a new commercial opportunity for Eden which is relevant to all of the products that we have developed and continue to develop using our three EU registered active ingredients.

"It is clear that there is growing demand from consumers within the EU for organic products and this is matched by rapidly growing production. Consequently, areas assigned by EU Member States for organic agriculture have grown by 70% in the last ten years* with organic retail sales reaching €34bn in 2017."

 

For further information contact:

Eden Research plc

www.edenresearch.com

Sean Smith

Alex Abrey

01285 359 555

 

 

 

Cenkos Securities (Nominated advisor and broker)

 

Giles Balleny / Cameron MacRitchie (corporate finance)Michael Johnson (sales)

020 7397 8900

 

 

 

Powerscourt (Financial PR)

 

Nick Dibden

Courtney Sanford

020 7250 1446

eden@powerscourt-group.com

 

* A report from the European Commission into Organic farming in the EU, published March 2019.

https://ec.europa.eu/info/sites/info/files/food-farming-fisheries/farming/documents/market-brief-organic-farming-in-the-eu_mar2019_en.pdf

 

Notes:

 

Eden Research is an AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries

 

Eden's Sustaineä encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can be used with both natural and synthetic compounds to enhance their performance and ease-of-use.

 

Sustaine microcapsules are naturally derived, plastic-free, biodegradable micro-spheres derived from yeast extract. They produce stabilised aqueous suspensions which, are easy to mix and apply, have phased release patterns, are safer for the environment and the crops themselves.

 

The European Chemicals Agency (ECHA) has proposed an EU-wide restriction on the placing on the market or use of "intentionally-added" microplastic particles. The proposed restriction includes the use of microplastics for agricultural and horticultural purposes, including polymers utilized for controlled-release fertilizers, encapsulated plant protection products (PPPs), seed coatings, and biocides.

 

By 2025 in the EU, pesticides containing synthetic polymer microplastics are likely to be banned and removed from the market. The only acceptable alternative is the substitution with biodegradable formulations. Reformulated products will need to be evaluated and registered within the five-year transition period.

 

Sustaine is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Sustaine provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

 

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £14m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements. 

 

In May 2013, the three actives that comprise Eden's first commercial product, Mevalone, were approved as new ingredients for use in plant protection products by the European Commission ("EC"). This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

 

Mevaloneä is a foliar fungicide which has been authorised for sale in Kenya, Malta, Greece, Bulgaria,

Spain, Italy, France, Cyprus, Albania, Portugal and Macedonia.

 

Cedrozä is a nematicide which has been authorised for sale in Malta, Belgium and Mexico.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

 

For more information about Eden, please visit: www.edenresearch.com.

 

 

 

 

END

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
READZGGMGVDGGZZ
Date   Source Headline
7th Jun 20227:00 amRNSInvestor Meet Company: 2021 Results Presentation
31st May 202210:29 amRNSDirector/PDMR Shareholding
31st May 20227:00 amRNSPreliminary results
16th May 20225:05 pmRNSHolding(s) in Company
10th May 20227:00 amRNSRegulatory update
2nd Mar 20227:00 amRNSTrading Update
2nd Dec 20217:00 amRNSNew Major Crop Use for Mevalone in France
20th Oct 20217:00 amRNSAdmission to the US OTC Market
28th Sep 20217:00 amRNSHalf Yearly Report
24th Sep 202112:32 pmRNSNotice of General Meeting
1st Sep 20217:00 amRNSIssuing of Annual Report & Notice of GM
26th Aug 20217:00 amRNSNew label extension for biofungicide in Portugal
28th Jul 20212:53 pmRNSDirector/PDMR Shareholding
27th Jul 20217:00 amRNSAgreement with Sipcam in North Africa
23rd Jul 20217:00 amRNSGrant of Awards under Long-Term Incentive Plan
12th Jul 20214:10 pmRNSHolding(s) in Company
5th Jul 20217:00 amRNSRegulatory approvals
1st Jul 202112:19 pmRNSPublication of Report and Accounts
30th Jun 202112:03 pmRNSResult of AGM
30th Jun 20217:00 amRNSPreliminary Results for Year Ended 31 Dec 2020
29th Jun 202111:27 amRNSVirtual Investor Conference – Link for webinar
7th Jun 20213:28 pmRNSNotice of AGM, investor conference & Accounts
12th May 20217:00 amRNSMilestone Agreement signed with Corteva
10th May 20217:00 amRNSRegulatory approval for Cedroz™ in Italy
1st Apr 20217:00 amRNSGrant of Awards under Long-Term Incentive Plan
31st Mar 20217:00 amRNSNew authorisations for bio-fungicide in Spain
29th Mar 20211:27 pmRNSHolding(s) in Company
19th Feb 20214:41 pmRNSSecond Price Monitoring Extn
19th Feb 20214:35 pmRNSPrice Monitoring Extension
19th Feb 20212:05 pmRNSSecond Price Monitoring Extn
19th Feb 20212:01 pmRNSPrice Monitoring Extension
11th Feb 20219:05 amRNSSecond Price Monitoring Extn
11th Feb 20219:00 amRNSPrice Monitoring Extension
11th Feb 20217:00 amRNSYear end trading update
5th Jan 20217:00 amRNSGreen Economy Mark
2nd Nov 20207:00 amRNSEden partners with M H Poskitt
13th Oct 20207:00 amRNSChange of Registered Office
29th Sep 20207:00 amRNSHalf-year Report
17th Sep 20207:00 amRNSNew authorisations for Cedroz™ and Mevalone®
15th Sep 20207:00 amRNSKey patent granted for Eden’s Sustaine technology
1st Sep 20207:00 amRNSRegulatory approval for Cedroz™ in Spain
25th Aug 20207:00 amRNSNew authorisation for bio-fungicide in Australia
5th Aug 20207:00 amRNSNew authorisation for Cedroz™ in Greece
10th Jul 20207:00 amRNSAppointment of Global Head of Biology and Dev
1st Jul 20207:00 amRNSNew office and laboratory in Oxfordshire
25th Jun 20207:00 amRNSPatents granted in the United States
24th Jun 202012:20 pmRNSResult of AGM
29th May 20207:58 amRNSIssuing of Annual Report & Notice of AGM
27th May 20207:00 amRNSUpdate on Bayer Animal Health Agreement
20th May 20207:00 amRNSNew authorisations for Cedroz and Mevalone

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.